Allogene Therapeutics
Jake Furber started their career as an Information Analyst at Broderbund Software in 1992. Jake then joined JDEDwards as an Engagement Manager. In 2003, they joined Gilead Sciences as an Associate Director of Financial Systems and stayed there for 10 years. Jake then moved on to Onyx Pharmaceuticals as a Director of Finance Processes. After that, they worked at Lending Club as a Financial System Director from 2014 to 2016. Jake then joined Ultragenyx Pharmaceutical Inc. as a Sr. Director of IT - G&A for two years. From 2018 to 2019, they worked at Sangamo Therapeutics, Inc. as a Senior Director of IT Enterprise Systems. Currently, they are working at Allogene Therapeutics as a Senior Director of IT - Corporate Systems.
Jake Furber attended Humboldt State University from 1988 to 1991, where they obtained a Bachelor of Science (B.S.) degree in CIS & Accounting.
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.